Meros Investment Management LP Lowers Holdings in BioLife Solutions, Inc. $BLFS

Key Points

• Meros Investment Management LP reduced its stake in BioLife Solutions by 20.4%, selling 33,795 shares and owning 131,650 shares, which now constitutes 1.8% of its overall portfolio.
• Institutions collectively own 93.24% of BioLife Solutions, with various investors like Point72 Asia and US Bancorp DE altering their holdings significantly in recent quarters.
• Recent analyst ratings show a consensus outlook of "Moderate Buy" for BioLife Solutions, with price targets ranging up to $32.00 following recent evaluations.

Meros Investment Management LP decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 20.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 131,650 shares of the medical equipment provider's stock after selling 33,795 shares during the period. BioLife Solutions makes up about 1.8% of Meros Investment Management LP's portfolio, making the stock its 27th biggest position. Meros Investment Management LP owned about 0.28% of BioLife Solutions worth $3,007,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions during the 4th quarter worth $31,000. US Bancorp DE raised its stake in BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 1,528 shares in the last quarter. GAMMA Investing LLC raised its stake in BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after acquiring an additional 663 shares in the last quarter. Avantax Advisory Services Inc. lifted its holdings in shares of BioLife Solutions by 16.0% in the first quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider's stock worth $207,000 after acquiring an additional 1,250 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at approximately $254,000. Institutional investors and hedge funds own 93.24% of the company's stock.

BioLife Solutions Trading Up 1.8%

Shares of BLFS stock traded up $0.4390 on Wednesday, hitting $24.9790. The company had a trading volume of 316,092 shares, compared to its average volume of 482,219. The stock's 50-day moving average is $22.19 and its two-hundred day moving average is $23.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.45 and a current ratio of 4.43. The firm has a market cap of $1.20 billion, a P/E ratio of -208.14 and a beta of 1.76. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The firm had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Transactions at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $23.80, for a total transaction of $23,800,000.00. Following the sale, the insider owned 7,707,165 shares in the company, valued at $183,430,527. This represents a 11.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 1,508,831 shares of company stock valued at $35,299,658 in the last quarter. 2.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

BLFS has been the subject of a number of research analyst reports. Wall Street Zen cut shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. HC Wainwright reiterated a "buy" rating and issued a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Stephens began coverage on BioLife Solutions in a report on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price objective on the stock. Finally, Zacks Research raised BioLife Solutions to a "strong-buy" rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat, BioLife Solutions currently has an average rating of "Buy" and an average target price of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.